HUS and TTP: traversing the disease and the age spectrum.

[1]  G. Remuzzi,et al.  CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome , 2023, Frontiers in Immunology.

[2]  M. van Meurs,et al.  Acute and chronic histopathological findings in renal biopsies in COVID-19 , 2022, Clinical and Experimental Medicine.

[3]  E. Adang,et al.  Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study , 2022, Kidney international reports.

[4]  Sumedha Bagga,et al.  Anti-factor H antibody and its role in atypical hemolytic uremic syndrome , 2022, Frontiers in Immunology.

[5]  A. C. Simões e Silva,et al.  The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review , 2022, Pediatric Nephrology.

[6]  S. Kirk,et al.  Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children , 2022, Frontiers in Immunology.

[7]  M. Scully,et al.  Advances in the management of TTP. , 2022, Blood reviews.

[8]  C. Vigneau,et al.  What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study , 2022, BMC Nephrology.

[9]  E. Klein,et al.  Improving Care for Children with Bloody Diarrhea at Risk for Hemolytic Uremic Syndrome , 2022, Pediatric quality & safety.

[10]  J. George,et al.  Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura , 2021, Blood advances.

[11]  S. Shawky,et al.  Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome , 2021, International Journal of Nephrology.

[12]  M. V. G. de Lacerda,et al.  Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases , 2021, PLoS neglected tropical diseases.

[13]  É. Azoulay,et al.  Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era , 2021, PloS one.

[14]  C. Jenkins,et al.  The emerging importance of Shiga toxin-producing Escherichia coli other than serogroup O157 in England , 2021, Journal of medical microbiology.

[15]  P. Griffin,et al.  Shiga Toxin-Producing Escherichia coli Outbreaks in the United States, 2010–2017 , 2021, Microorganisms.

[16]  F. Weill,et al.  Shiga Toxin–Associated Hemolytic Uremic Syndrome in Adults, France, 2009–2017 , 2021, Emerging infectious diseases.

[17]  G. Del Angel,et al.  Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification , 2021, Blood.

[18]  É. Azoulay,et al.  Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era , 2021, Critical care medicine.

[19]  R. Cunney,et al.  Neurological involvement in children with hemolytic uremic syndrome , 2021, European Journal of Pediatrics.

[20]  G. Ardissino,et al.  Bloody Diarrhea and STEC-HUS in Children: Data from the ItalKid-HUS Network. , 2021, The Journal of pediatrics.

[21]  S. Latifi,et al.  Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine , 2021, Pathogens.

[22]  M. Kemper,et al.  Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS) , 2021, Pediatric Nephrology.

[23]  P. Coppo,et al.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management , 2021, Toxins.

[24]  J. Webb,et al.  Erythrocyte T‐antigen activation in children: Patient characteristics and the hemolytic risk of transfusion , 2021, Pediatric blood & cancer.

[25]  J. Harambat,et al.  Treatment strategy for Streptococcus pneumoniae-associated hemolytic uremic syndrome , 2021, Pediatric Nephrology.

[26]  G. Ardissino,et al.  Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network , 2021, European Journal of Pediatrics.

[27]  P. Sánchez-Corral,et al.  Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome , 2021, Frontiers in Immunology.

[28]  J. George,et al.  Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children , 2021, Pediatric blood & cancer.

[29]  J. George,et al.  Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura. , 2021, Blood.

[30]  D. Müller,et al.  Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome , 2021, Pediatric Nephrology.

[31]  C. Reutelingsperger,et al.  Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes , 2021, Kidney international reports.

[32]  B. Lämmle,et al.  Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management , 2021, Journal of clinical medicine.

[33]  Cheng Cheng,et al.  Case Report: Denys–Drash Syndrome With WT1 Causative Variant Presenting as Atypical Hemolytic Uremic Syndrome , 2020, Frontiers in Pediatrics.

[34]  W. Hanf,et al.  Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study. , 2020, Blood.

[35]  Meera Sridharan,et al.  Complement in Secondary Thrombotic Microangiopathy , 2020, Kidney International Reports.

[36]  L. Alberio,et al.  Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. , 2020, Blood.

[37]  S. Vesely,et al.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura , 2020, Journal of thrombosis and haemostasis : JTH.

[38]  S. Rodríguez de Córdoba,et al.  The familial risk of developing atypical Hemolytic Uremic Syndrome. , 2020, Blood.

[39]  T. Wołkowicz,et al.  Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)‐producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland , 2020, Letters in applied microbiology.

[40]  D. Milford,et al.  Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy , 2020, Kidney international.

[41]  A. Metjian,et al.  Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura , 2020, Therapeutic advances in hematology.

[42]  C. Rafat,et al.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review , 2020, Toxins.

[43]  C. Reutelingsperger,et al.  Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy , 2019, Hypertension.

[44]  E. Gratacós,et al.  Complement Activation and Thrombotic Microangiopathies. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[45]  S. Ladhani,et al.  Pneumococcal-related Hemolytic Uremic Syndrome in the United Kingdom: National Surveillance, 2006-2016. , 2019, The Pediatric infectious disease journal.

[46]  Lawrence Copelovitch,et al.  New insights into the pathogenesis of Streptococcus pneumoniae–associated hemolytic uremic syndrome , 2019, Pediatric Nephrology.

[47]  P. van Paassen,et al.  Defects in complement and "secondary" hemolytic uremic syndrome. , 2019, Kidney international.

[48]  R. Furie,et al.  Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. , 2019, Seminars in arthritis and rheumatism.

[49]  S. Rotz,et al.  Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence , 2019, Pediatric blood & cancer.

[50]  G. Remuzzi,et al.  An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  C. Thongprayoon,et al.  Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis , 2019, Journal of clinical medicine.

[52]  N. Jourde-Chiche,et al.  Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. , 2019, Kidney international.

[53]  T. Coşkun,et al.  Do not Miss Rare and Treatable Cause of Early-Onset Hemolytic Uremic Syndrome: Cobalamin C Deficiency , 2019, Nephron.

[54]  G. Remuzzi,et al.  Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS , 2019, Front. Immunol..

[55]  A. Sinha,et al.  Hemolytic uremic syndrome in a developing country: Consensus guidelines , 2019, Pediatric Nephrology.

[56]  R. Liesner,et al.  Characterization and treatment of congenital thrombotic thrombocytopenic purpura. , 2019, Blood.

[57]  F. Petitprez,et al.  Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome , 2019, Haematologica.

[58]  T. Ruchutrakool,et al.  Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis , 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[59]  G. Remuzzi,et al.  Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome , 2019, Microorganisms.

[60]  J. Vande Walle,et al.  Is Plasma Exchange Efficacious in Shiga Toxin‐Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[61]  H. Dupont,et al.  Non-O157 Shiga toxin-producing Escherichia coli-A poorly appreciated enteric pathogen: Systematic review. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[62]  S. Andreoli,et al.  Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS) , 2018, Pediatric Nephrology.

[63]  É. Azoulay,et al.  Early Differentiation of Shiga Toxin–Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes , 2018, Critical care medicine.

[64]  P. Coppo,et al.  Pediatric thrombotic thrombocytopenic purpura , 2018, European journal of haematology.

[65]  G. Ardissino,et al.  Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. , 2018, Kidney international.

[66]  F. Fakhouri,et al.  Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. , 2018, Seminars in hematology.

[67]  C. Reutelingsperger,et al.  C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. , 2018, Journal of the American Society of Nephrology : JASN.

[68]  E. Tanner‐Smith,et al.  Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome , 2018 .

[69]  D. Kavanagh,et al.  Interventions for atypical haemolytic uraemic syndrome. , 2017, The Cochrane database of systematic reviews.

[70]  J. George,et al.  Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. , 2017, Blood advances.

[71]  S. Bonacorsi,et al.  Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. , 2017, Medecine et maladies infectieuses.

[72]  Dexuan Wang,et al.  Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia , 2017, Medicine.

[73]  P. Gipson,et al.  The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. , 2017, Journal of the American Society of Nephrology : JASN.

[74]  S. Johnson,et al.  Treatment and management of children with haemolytic uraemic syndrome , 2017, Archives of Disease in Childhood.

[75]  N. Prasad,et al.  P. vivax Malaria presenting as Thrombotic Microangiopathy. , 2017, The Journal of the Association of Physicians of India.

[76]  V. Frémeaux-Bacchi,et al.  Haemolytic uraemic syndrome , 2017, The Lancet.

[77]  G. Remuzzi,et al.  Hemolytic Uremic Syndrome in Pregnancy and Postpartum. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[78]  G. Remuzzi,et al.  Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis , 2017, The Journal of Immunology.

[79]  C. Reutelingsperger,et al.  Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. , 2017, Kidney international.

[80]  Ang Li,et al.  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. , 2017, The Lancet. Haematology.

[81]  G. Ardissino,et al.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[82]  T. Cavero,et al.  Eculizumab in secondary atypical haemolytic uraemic syndrome , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[83]  E. Volokhina,et al.  Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome , 2016, Pediatric Nephrology.

[84]  P. Ruggenenti,et al.  Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[85]  A. Diepstra,et al.  Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity , 2016, Pediatric Nephrology.

[86]  L. Hartling,et al.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  É. Azoulay,et al.  Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. , 2016, The Lancet. Haematology.

[88]  H. Lanfermann,et al.  Neurological Sequelae in Adults After E coli O104 , 2016, Medicine.

[89]  M. Noris,et al.  Thrombotic microangiopathy without renal involvement: two novel mutations in complement‐regulator genes , 2016, Journal of thrombosis and haemostasis : JTH.

[90]  G. Remuzzi,et al.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[91]  K. Mølbak,et al.  Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. , 2015, The Journal of antimicrobial chemotherapy.

[92]  P. Zipfel,et al.  Atypical aHUS: State of the art. , 2015, Molecular immunology.

[93]  J. Ruscasso,et al.  Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome , 2015, Pediatric Nephrology.

[94]  G. Remuzzi,et al.  Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[95]  W. Park,et al.  Atypical hemolytic uremic syndrome: Korean pediatric series , 2015, Pediatrics international : official journal of the Japan Pediatric Society.

[96]  P. Bierling,et al.  Red blood cell Thomsen‐Friedenreich antigen expression and galectin‐3 plasma concentrations in Streptococcus pneumoniae–associated hemolytic uremic syndrome and hemolytic anemia , 2015, Transfusion.

[97]  G. Remuzzi,et al.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies , 2015, Kidney international.

[98]  Francesco Tedesco,et al.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. , 2014, Blood.

[99]  J. Hofer,et al.  Extra-Renal Manifestations of Complement-Mediated Thrombotic Microangiopathies , 2014, Frontiers in Pediatrics.

[100]  K. van Besien,et al.  Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. , 2014, Clinical advances in hematology & oncology : H&O.

[101]  M. Ohnishi,et al.  Guidelines for the management and investigation of hemolytic uremic syndrome , 2014, Clinical and Experimental Nephrology.

[102]  Martyn D Kirk,et al.  Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. , 2014, Foodborne pathogens and disease.

[103]  A. Sinha,et al.  Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. , 2014, Kidney international.

[104]  F. Donnerstag,et al.  Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome , 2014, Pediatric Nephrology.

[105]  G. Remuzzi,et al.  Cardiovascular complications in atypical haemolytic uraemic syndrome , 2014, Nature Reviews Nephrology.

[106]  G. Remuzzi,et al.  Hemolytic uremic syndrome , 2014, Seminars in Immunopathology.

[107]  Machiko Kadoya,et al.  Decreased sialylation of IgA1 O‐glycans associated with pneumococcal hemolytic uremic syndrome , 2013, Pediatrics international : official journal of the Japan Pediatric Society.

[108]  B. Vendrely,et al.  Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[109]  T. Goodship,et al.  Atypical Hemolytic Uremic Syndrome , 2013, Seminars in nephrology.

[110]  G. Remuzzi,et al.  Overview of Complement Activation and Regulation , 2013, Seminars in nephrology.

[111]  S. Vesely,et al.  Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features , 2013, Pediatric blood & cancer.

[112]  S. Vesely,et al.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. , 2013, Blood.

[113]  U. Buchholz,et al.  Associations of age and sex with the clinical outcome and incubation period of Shiga toxin-producing Escherichia coli O104:H4 infections, 2011. , 2013, American journal of epidemiology.

[114]  Alejandro Balestracci,et al.  Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome , 2013, Pediatric Nephrology.

[115]  L. Rostaing,et al.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[116]  Lawrence Copelovitch,et al.  Update on Streptococcus pneumoniae associated hemolytic uremic syndrome , 2013, Current opinion in pediatrics.

[117]  John Hwa,et al.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome , 2013, Nature Genetics.

[118]  J. Moake,et al.  Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis , 2013, PloS one.

[119]  G. Remuzzi,et al.  Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. , 2013, Journal of the American Society of Nephrology : JASN.

[120]  A. Bakkaloğlu,et al.  DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. , 2013, Journal of the American Society of Nephrology : JASN.

[121]  Alejandro Balestracci,et al.  Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome , 2013, Pediatric Nephrology.

[122]  S. Agarwal,et al.  Thrombotic microangiopathy and acute kidney injury following vivax malaria , 2013, Clinical and Experimental Nephrology.

[123]  Lawrence Copelovitch,et al.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome , 2013, Pediatric Nephrology.

[124]  G. Remuzzi,et al.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation , 2012, Nature Reviews Nephrology.

[125]  A. Kribben,et al.  Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[126]  Ulrich C. Klostermeier,et al.  Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study , 2012, BMJ : British Medical Journal.

[127]  C. Gerloff,et al.  The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. , 2012, Brain : a journal of neurology.

[128]  J. Knobloch,et al.  Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. , 2012, JAMA.

[129]  G. Remuzzi,et al.  A German outbreak of haemolytic uraemic syndrome , 2011, The Lancet.

[130]  S. Vesely,et al.  Systemic infections mimicking thrombotic thrombocytopenic purpura , 2011, American journal of hematology.

[131]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[132]  L. Gould,et al.  POSTDIARRHEAL HEMOLYTIC UREMIC SYNDROME IN PERSONS AGED 65 AND OLDER IN FOODNET SITES, 2000–2006 , 2011, Journal of the American Geriatrics Society.

[133]  G. Remuzzi,et al.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[134]  G. Remuzzi,et al.  Thrombotic Microangiopathy After Kidney Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[135]  P. Galieni,et al.  High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study , 2010, Annals of Hematology.

[136]  C. Sautès-Fridman,et al.  Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. , 2010, Kidney international.

[137]  D. Lambrechts,et al.  Thrombomodulin mutations in atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[138]  G. Remuzzi,et al.  Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies , 2009, Thrombosis and Haemostasis.

[139]  W. Fridman,et al.  Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. , 2008, Blood.

[140]  E. Thervet,et al.  Complement Mutation‐Associated De Novo Thrombotic Microangiopathy Following Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[141]  S. Vesely,et al.  Sporadic bloody diarrhoea‐associated thrombotic thrombocytopenic purpura‐haemolytic uraemic syndrome: an adult and paediatric comparison , 2008, British journal of haematology.

[142]  G. Remuzzi,et al.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.

[143]  F. Huang,et al.  T-antigen Activation for Prediction of Pneumococcus-Induced Hemolytic Uremic Syndrome and Hemolytic Anemia , 2006, The Pediatric infectious disease journal.

[144]  S. Madhi,et al.  Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining? , 2006, The Lancet Infectious Diseases.

[145]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[146]  L. Ravà,et al.  Risk factors for poor renal prognosis in children with hemolytic uremic syndrome , 2003, Pediatric Nephrology.

[147]  S. Vesely,et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. , 2003, Blood.

[148]  N. Perico,et al.  von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 2002, Blood.

[149]  P. Ruggenenti,et al.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. , 2001, Kidney international.

[150]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[151]  P. Mead,et al.  Escherichia coli O157:H7 , 1998, The Lancet.

[152]  N. Bibiloni,et al.  Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features , 1997, Pediatric Nephrology.

[153]  R. Christofferson,et al.  A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. , 1994, Pediatrics.

[154]  G. Remuzzi,et al.  HUS and TTP: Variable expression of a single entity , 1987 .

[155]  H. Rennke,et al.  De novo thrombotic microangiopathy after kidney transplantation. , 2018, Transplantation reviews.

[156]  U. Kunzendorf,et al.  Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome. , 2017, Transfusion medicine reviews.

[157]  J. Knobloch,et al.  Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[158]  G. Remuzzi,et al.  A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. , 2015, Journal of the American Society of Nephrology : JASN.

[159]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).